Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 18/20 | 0.59 |
| ▸ | PTGER2 | P43116 | 11/20 | 0.55 |
| ▸ | PTGER3 | P43115 | 10/20 | 0.55 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.44 |
| ▸ | PTGIR | P43119 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6614638 | 1.00 | PTGER4 (0.59) | PTGER4PTGER2PTGER3PTGER1PTGIR | |
| SCHEMBL5219518 | 1.00 | PTGER4 (0.59) | PTGER4PTGER2PTGER3PTGER1PTGIR | |
| SCHEMBL5216829 | 1.00 | PTGER4 (0.59) | PTGER4PTGER2PTGER3PTGER1PTGIR | |
| SCHEMBL5219510 | 1.00 | PTGER4 (0.59) | PTGER4PTGER2PTGER3PTGER1PTGIR | |
| SCHEMBL5213647 | 0.90 | PTGER4 (0.73) | PTGER4PTGER2PTGER3PTGER1PTGIR | |
| SCHEMBL5213653 | 0.90 | PTGER4 (0.73) | PTGER4PTGER2PTGER3PTGER1PTGIR | |
| SCHEMBL5213650 | 0.90 | PTGER4 (0.73) | PTGER4PTGER2PTGER3PTGER1PTGIR | |
| SCHEMBL5213643 | 0.90 | PTGER4 (0.73) | PTGER4PTGER2PTGER3PTGER1PTGIR | |
| SCHEMBL5215685 | 0.85 | PTGER4 (0.41) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL5215669 | 0.85 | PTGER4 (0.41) | PTGER4PTGER2PTGER3PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1408961-B1 | 2 PYRROLIDONE DERIVATIVES AS PROSTANOID AGONISTS | HOFFMANN LA ROCHE (CH) | 2007-07-11 | — | — | EP | disclosed |
| US-6849657-B2 | 2-pyrrolidone derivatives as prostanoid agonists | SYNTEX (U.S.A.) LLC (US) | 2005-02-01 | — | — | US | disclosed |
| EP-1408961-A1 | 2 PYRROLIDONE DERIVATIVES AS PROSTANOID AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-21 | — | — | EP | disclosed |
| US-20030064964-A1 | 2-pyrrolidone derivatives as prostanoid agonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-04-03 | — | — | US | disclosed |
| WO-2003007941-A1 | 2 PYRROLIDONE DERIVATIVES AS PROSTANOID AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064964-A1 | 2-pyrrolidone derivatives as prostanoid agonists | PTGER1, PTGER4, PTGIR | PTGER4 2/4885PTGER2 4/4885PTGER3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.